Profil
Kenneth A. Bauer has been a Director of GTC Biotherapeutics, Inc. since December 2004, Director of Thrombosis Clinical Research for the Beth Israel Deaconess Medical Center since 1997 and Professor of Medicine at the Harvard Medical School since 2004.
Dr. Bauer has been a Faculty Member of the Harvard Medical School since 1982.
He is Chairman of Council for the International Society on Thrombosis and Haemostasis.
He received a BS and an MS from the Massachusetts Institute of Technology and his Medical Education from the Stanford University School of Medicine.
He completed subspecialty training in medical oncology and hematology at the Dana Farber Cancer Institute and Beth Israel Hospital in Boston.
Aktiva positioner av Kenneth A. Bauer
| Företag | Position | Start |
|---|---|---|
The International Society of Thrombosis & Hemostasis | Företagsledare/Principal | - |
Tidigare kända positioner av Kenneth A. Bauer
| Företag | Position | Slut |
|---|---|---|
| REVO BIOLOGICS INC | Direktör/Styrelseledamot | 2009-10-01 |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Företagsledare/Principal | - |
Kenneth A. Bauers utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Beth Israel Deaconess Medical Center, Inc.
Beth Israel Deaconess Medical Center, Inc. Hospital/Nursing ManagementHealth Services Provides healthcare services | Health Services |
The International Society of Thrombosis & Hemostasis | |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
















